The company has also received renewed research funding from the National Institutes of Health (NIH) to continue preclinical development of severe acute respiratory syndrome (SARS) vaccine candidates using Novavax’s virus-like particle (VLP) technology.
The SARS VLP program is conducted under an NIH grant. Novavax does not have the commercial rights to this product candidate.
Rahul Singhvi, president and CEO of Novavax, said: “This new approach to create VLPs will allow us to continue our work to develop a SARS vaccine candidate and expand the potential applications of our vaccine technology to a broad range of infectious diseases around the world.”